Product Overview
Tirzepatide, also known as LY3298176, combines GIP and GLP-1 receptor activity. That dual design expands the research model beyond a standard GLP-1 agonist by bringing nutrient-responsive GIP signaling into the same compound.
GLP-1 is closely associated with appetite, gastric activity, insulin response, and glucose regulation. GIP adds another layer involving nutrient sensing, insulin secretion, and lipid metabolism. Together, they support research into glycemic control, energy intake, adiposity, body composition, and the broader coordination of metabolic signaling.
For laboratories comparing incretin platforms, Tirzepatide remains the defining dual agonist and a natural reference point between single-pathway and triple-pathway compounds.
Common Research Areas
⦁ GIP and GLP-1 receptor signaling
⦁ Glucose and insulin response
⦁ Appetite and satiety pathways
⦁ Lipid metabolism
⦁ Body-weight and body-composition research
Research References
- Coskun T, et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity.” Molecular Metabolism. 2018;17:104-116. DOI: 10.1016/j.molmet.2018.06.001.
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” The New England Journal of Medicine. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038.
